|
|
 | | | |
- close
- close
- close
- close
Pharma's Cutting Edge
Dec 28
Comment
Genitope's Webcast
A week ago Genitope reported the results of a pivotal Phase 3 trial for its only clinical candidate, the idiotype-specific, personalized active immunotherapy for Non-Hodgkin's Lymphoma, known as MyVax. I've been...
Suggest other news sources for this topic
more ▼WIKI ANALYSIS
WIKI ANALYSIS
 |
The article on this company has not been written yet. If you're the first person to write this article, it's a sure thing that you'll be credited as a Top Contributor. For tips on getting started, check out the sample article. |
TOP CONTRIBUTORS
Genitope (GTOP) primarily fights follicular Non Hogkins Lymphoma via two products. The first is MyVax which is a cancer vaccine. The origin of the vaccine is Dr. Levy from Stanford. Stanford has been vaccinating patients for nearly 3 decades. In that time they have learned that people with a valine valine idiotype are most easily treated and many indatations, though anecdotes, are that such people can be completely curred. The current CEO is Dan Deny, who has been said to be Dr. Levy's favorite student. Currently toward the end of a phase three trial, with fast track FDA approval, the last patient comes in for follow up in November 2007. Data should be available within two months.
The second is via a palet of antibiotics. It has been said that in many patients tumor mass can be decreased by 80% or so within only a few weeks. FDA is usually comfortable testing one antibiotic at a time. However with NHL, there are basically 25 expressions of the cell and people have only one type of cell expressed. One antibiotic works per expression.
What makes NHL a reasonable candidate for vaccination is that the cell don't mutate and mutate again. They tend to mutate and make "perfect" replicas on the cancerous cell.
References
| |||||||
